Improving Prognostication in Colon Cancer

Inclusion Criteria:

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
2. Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).
3. Newly diagnosed primary colon tumor clinically and/or histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.
4. Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.
5. WHO (ECOG) performance status ≤ 3 at baseline.

Exclusion Criteria:

1. Participant has been diagnosed with metastatic disease (Stage IV)
2. Participant has been diagnosed with rectal cancer
3. Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)
4. Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer
5. Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.
6. Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.
7. Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).